IMHO a big catalyst will be results of preclinical trials into other neurodegenerative indications.
At the moment we have all our eggs in the ALS basket which carries a fair amount of risk. If it looks like we can bring a second indication into play then that both increases our addressable market and also spreads the risk.
I'd imagine that strong preclinical results in a second indication could easily result in a doubling of the current share price.
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-907
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.3¢ |
Change
0.013(7.35%) |
Mkt cap ! $87.51M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.5¢ | 17.5¢ | $262.3K | 1.462M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 211665 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 148446 | 3 |
View Market Depth
| Last trade - 11.35am 26/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |